Spyre Therapeutics

Spyre Therapeutics is a biotechnology startup founded in 2013 and based in the United States. The company's slogan, "Engineering for new heights in the treatment of inflammatory bowel disease," encapsulates its mission to revolutionize treatments for this condition. By combining best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches, Spyre Therapeutics aims to maximize the efficacy, safety, and convenience of treatments for inflammatory bowel disease.

The most recent milestone for Spyre Therapeutics was a Post-IPO Equity investment at 18 March 2024. Notable investors in this round include Boxer Capital, Adage Capital Management, Deep Track Capital, Logos Capital, Perceptive Advisors, RTW Investments, Avidity Partners, Farallon Capital Management, and Darwin Global.

This latest injection of capital demonstrates the confidence and support of a diverse group of investors in Spyre Therapeutics' innovative approach and potential to make a significant impact in the biotechnology industry. With strategic partnerships and a focus on addressing critical medical needs, Spyre Therapeutics is poised to make meaningful advancements in the treatment of inflammatory bowel disease.